These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Use of pharmacoeconomics in prescribing research. Part 5: modelling--beyond clinical trials. Lang DL; Lopert R; Hill SR J Clin Pharm Ther; 2003 Oct; 28(5):433-9. PubMed ID: 14632969 [TBL] [Abstract][Full Text] [Related]
3. Evaluation and review of pharmacoeconomic models. Hay JW Expert Opin Pharmacother; 2004 Sep; 5(9):1867-80. PubMed ID: 15330725 [TBL] [Abstract][Full Text] [Related]
4. Interest of modelling in rheumatoid arthritis. Beresniak A; Dupont DM; Becker JC; Merkesdal S Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S96-101. PubMed ID: 23078913 [TBL] [Abstract][Full Text] [Related]
5. Decision-analytical modelling in health-care economic evaluations. Sun X; Faunce T Eur J Health Econ; 2008 Nov; 9(4):313-23. PubMed ID: 17943332 [TBL] [Abstract][Full Text] [Related]
12. Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations. Nuijten MJ Pharmacoeconomics; 2004; 22(12):759-69. PubMed ID: 15294010 [TBL] [Abstract][Full Text] [Related]
13. Introduction to Cost Analysis in IR: Challenges and Opportunities. Roudsari B; McWilliams J; Bresnahan B; Padia SA J Vasc Interv Radiol; 2016 Apr; 27(4):539-545.e1. PubMed ID: 26922978 [TBL] [Abstract][Full Text] [Related]
14. Health economic models: a question of balance--summary of an open discussion on the pharmacoeconomic evaluation of non-steroidal anti-inflammatory drugs. Drummond MF Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():29-32. PubMed ID: 11276799 [TBL] [Abstract][Full Text] [Related]
15. Decision analysis and economic modelling: a primer. Inadomi JM Eur J Gastroenterol Hepatol; 2004 Jun; 16(6):535-42. PubMed ID: 15167154 [TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomics: state of the art in 1997. Schulman KA; Linas BP Annu Rev Public Health; 1997; 18():529-48. PubMed ID: 9143730 [TBL] [Abstract][Full Text] [Related]
17. Penny and pound wise: pharmacoeconomics from a governmental perspective. van Oostenbruggen MF; Jansen RB; Mur K; Kooijman H Pharmacoeconomics; 2005; 23(3):219-26. PubMed ID: 15836004 [TBL] [Abstract][Full Text] [Related]
18. Principles of pharmacoeconomic analysis of drug therapy. Freund DA; Dittus RS Pharmacoeconomics; 1992 Jan; 1(1):20-31. PubMed ID: 10147037 [TBL] [Abstract][Full Text] [Related]
19. [Disease modelling in diabetes mellitus]. Schramm W; Schöffski O; Görtz A; Liebl A Dtsch Med Wochenschr; 2004 Oct; 129(43):2305-10. PubMed ID: 15483770 [TBL] [Abstract][Full Text] [Related]
20. The rationale of pharmacoeconomic analysis in rheumatologic indications. Turchetti G; Scalone L; Della Casa Alberighi O; Mosca M; Montella S; Cortesi PA; Mantovani LG Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S64-71. PubMed ID: 23072796 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]